Esclerosis múltiple como efecto adverso de los agentes antifactor de necrosis tumoral alfa: una complicación infrecuente pero relevante de infliximab en la enfermedad de Crohn

Subías, Alberto Mir; García-López, Santiago; Torres, Berta; Domenche, Leticia Ollero; Gámez, Andrés García; Gomollón, Fernando

doi:10.1016/j.gastrohep.2012.07.001

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some biological drugs, especially anti-TNFα, may increase the risk of developing demyelinating diseases ( 82 , 83 ). In addition, rare reports of demyelinating polyneuropathies have been published (including Guillain-Barré syndrome, inflammatory demyelinating polyneuropathy, demyelinating polyneuropathy and multi focal motor neuropathy).…”

Section: Resultsmentioning

confidence: 99%

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Perricone,

Castellucci,

Cafaro

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The treatment of patients with rheumatoid arthritis (RA) has dramatically changed in the past 30 years. Currently, numerous conventional, biologic, and targeted synthetic DMARDs have been licensed and used following recommendations provided by international and national scientific societies. However, the availability of biosimilars and the increasing necessity of savings impacted on the local/national prescription of these drugs. The information provided by data sheet of every single drug is a decisive factor on the choice of a certain treatment merged with the patient’s profile. Thus, our purpose was to construct a rational algorithm for the treatment strategy in RA according to costs and the product leaflet of the biologic and targeted-synthetic DMARDs currently licensed in Italy. We used the most recent available recommendations and then we performed a review of the literature considering all the factors that are known to influence drug safety/effectiveness. All these factors were considered in the context of the data sheets of currently available originators and biosimilars.

show abstract

Section: Resultsmentioning

confidence: 99%

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Perricone,

Castellucci,

Cafaro

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Infliximab

2014

Reactions Weekly

View full text Add to dashboard Cite

Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients

Felice

Novotná

Enders

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Anti-TNFα biologics induce and maintain remission in inflammatory bowel disease (IBD). Also, they have been reported to induce or unmask idiopathic inflammatory demyelinating disease of the central nervous system (IIDD). Aim To determine if anti-TNFα biologics increased the risk of IIDD in a large cohort of patients with IBD. Methods We retrospectively identified adult patients referred to the Mayo Clinic, Rochester, MN for management of IBD from a five state capture area (Minnesota, Wisconsin, North Dakota, South Dakota, and Iowa) between 1996 and 2010. IIDDs were identified in both Crohn’s disease (CD) and ulcerative colitis (UC) patients with and without anti-TNFα exposure using the 2010 McDonald MRI criteria. The risk of IIDDs in patients with and without anti-TNFα exposure was estimated for IBD; CD and UC groups separately. Results A total of 9095 patients with IBD were identified (4342 CD and 4753 UC). Four patients with CD with exposure to anti-TNFα agents (4/2054) and five patients with CD without anti-TNFα exposure (5/2288) developed a confirmed IIDD. One patient with UC with exposure to anti-TNFα agents (1/1371) and five patients with UC without anti-TNFα agents developed a confirmed IIDD (5/3382). The percent of IIDDs in patients with and without anti-TNFα exposure was; IBD: 0.15% and 0.18% (RR=0.83, 95%CI: 0.28-2.42; p=0.729); CD: 0.19% and 0.22% (RR=0.89, 95%CI: 0.24-3.31; p=0.863); UC: 0.07% and 0.15% (RR=0.49, 95%CI: 0.06-4.22; p=0.510). Conclusions Anti-TNFα biologics do not appear to impact the risk of developing clinical IIDD in patients with IBD.

show abstract

Esclerosis múltiple como efecto adverso de los agentes antifactor de necrosis tumoral alfa: una complicación infrecuente pero relevante de infliximab en la enfermedad de Crohn

Cited by 4 publications

References 26 publications

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy

Infliximab

Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients

Contact Info

Product

Resources

About